THC Pharm

THC Pharm is a specialized German pharmaceutical company that pioneered the medical use of cannabinoids in Europe. Founded in 1996 and headquartered in Frankfurt, the company was the first to manufacture and distribute Dronabinol (synthetic THC) for pharmaceutical use in Germany. It focuses on the production of high-purity cannabinoids and standardized formulations for pharmacies, supporting treatments for chronic pain, multiple sclerosis, and oncology-related symptoms. In 2019, THC Pharm was acquired by Canopy Growth Corporation as part of its acquisition of the C3 Cannabinoid Compound Company. The company remains a critical component of the global medical cannabis supply chain, providing GMP-certified active pharmaceutical ingredients. Its expertise includes the semi-synthetic synthesis of cannabinoids and the development of magistral preparations.